Pipeline

Building a Broad Pipeline of
Indications

Mechanism of Action: Leronlimab as a CCR5 antagonist

Program Indication Pre-clinical Phase 1 Phase 2 Phase 3
HIV
Combination Therapy
(Fast Track designation)
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Monotherapy
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Pre-exposure prophylaxis (PrEP)
Pre-clinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Oncology
Triple-Negative Breast
(Fast Track designation)
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Basket trial for 22 solid tumors
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
NASH
Non-alcoholic steatohepatitis (NASH)
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
COVID-19
COVID-19 Acute Severe
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
COVID-19 Acute Critical
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
COVID-19 Post-Acute (long haulers)
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
MS
Multiple Sclerosis (MS)
Pre-clinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

Leronlimab for HIV Treatment

Our lead product, leronlimab (PRO 140), is a subcutaneous injection for HIV that prevents healthy cells from viral entry.

Read More on Leronlimab

Leronlimab for Cancer Metastasis

Recent research demonstrates the potential importance of the CCR5 receptor as a therapeutic target in oncology.

Read More on CCR5

Coronavirus Disease 2019

CytoDyn is coordinating with several healthcare partners to provide access to leronlimab for COVID-19 patients through two clinical trials, a Phase 2 trial for those with mild-to-moderate indications and a Phase 2b/3 trial for severe and critically ill patients.

Read More on COVID-19

Get In Touch

For more information on leronlimab, our science, or our new developments, please reach out to us using the link provided.

Ask a Question